1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Drugs In Development, 2022, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Dengue Fever - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 10, 39, 20 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 12 and 15 molecules, respectively.
Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Dengue Fever - Overview
- Dengue Fever - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Dengue Fever - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Dengue Fever - Companies Involved in Therapeutics Development
- Dengue Fever - Drug Profiles
- Dengue Fever - Dormant Projects
- Dengue Fever - Discontinued Products
- Dengue Fever - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Dengue Fever, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Dengue Fever - Dormant Projects, 2022
- Dengue Fever - Discontinued Products, 2022
- Number of Products under Development for Dengue Fever, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 60 Degrees Pharmaceuticals LLC
- Abhelix LLC
- Abivax SA
- AbViro LLC
- Acer Therapeutics Inc
- Atea Pharmaceuticals Inc
- Avida Biotech SL
- Biological Mimetics Inc
- BioNet-Asia Co Ltd
- Biotron Ltd
- Bugworks Research Inc
- Cidara Therapeutics Inc
- Codagenix Inc
- Decoy Therapeutics Inc
- Emergex Vaccines Holding Ltd
- Ennaid Therapeutics LLC
- Etna Biotech Srl
- Excivion Ltd
- Exopharm Ltd
- Globavir Biosciences Inc
- Greffex Inc
- Hercules Pharmaceuticals BV
- HSRx Group
- ImmuneMed Inc
- Immunotope Inc
- Imutex Ltd
- Indian Immunologicals Ltd
- Inovio Pharmaceuticals Inc
- Integral Molecular Inc
- Island Pharmaceuticals Ltd
- Johnson & Johnson
- KARE Biosciences Inc
- KinoPharma Inc
- KM Biologics Co Ltd
- Mabloc LLC
- Macrophage Therapeutics Inc
- Medigen Inc
- Meletios Therapeutics SAS
- Moleculin Biotech Inc
- Najit Technologies Inc
- NanoViricides Inc
- Novartis AG
- Panacea Biotec Ltd
- Plex Pharmaceuticals Inc
- ProtInhi BV
- ReVacc Biotech
- Riboscience LLC
- Seagull BioSolutions Pvt Ltd
- Serum Institute of India Pvt Ltd
- Shionogi & Co Ltd
- Sun Pharma Advanced Research Company Ltd
- Takeda Pharmaceutical Co Ltd
- TechnoVax Inc
- TenGen Biomedical Co
- Theravectys SA
- TrippBio Inc
- Uvax Bio LLC
- Vir Biotechnology Inc
- Virocovax
- Visterra Inc
- VLP Therapeutics LLC
- Xenothera SAS
- Zucero Therapeutics Ltd
- Zydus Lifesciences Ltd
